Identification
- Composition (DCI)
- satralizumab
- Manufacturer
- ROCHE S.A
- ATC code
- L04AC19
- Presentation
- Boite unitaire
- Schedule / Reimb.
- A
- Hospital price
- 67400.00 MAD
Indications
Enspryng est utilisé en monothérapie ou en association avec un traitement immunosuppresseur (TIS) dans le traitement des maladies du spectre de la neuromyélite optique (NMOSD) chez les adultes et les adolescents présentant des anticorps IgG anti-aquaporine-4 (c.-à-d. séropositifs pour les IgG anti-AQP4). Source : Compendium.ch - Date : 20 octobre 2025
Find an open pharmacy
On-call pharmacies near you
About ENSPRYNG 120 MG / 1 ML
ENSPRYNG 120 MG / 1 ML is marketed in Morocco by ROCHE S.A and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of ENSPRYNG 120 MG / 1 ML, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about ENSPRYNG 120 MG / 1 ML
Answers to common questions from Moroccan patients about this drug.